Bolt Biotherapeutics saw the highest growth of 2.99% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw no growth in patent filings and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Bolt Biotherapeutics’s patent filings and grants. Buy the databook here.
Bolt Biotherapeutics has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with two publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 50% of filings. The World Intellectual Property Organization(WIPO), European Patent Office(EPO), United States(US), and Australia(AU) patent Office are among the top ten patent offices where Bolt Biotherapeutics is filings its patents. Among the top granted patent authorities, Bolt Biotherapeutics has 100% of its grants in Australia(AU).
Roche and Johnson & Johnson could be the strongest competitors for Bolt Biotherapeutics
Patents related to nanomedicine and rare diseases lead Bolt Biotherapeutics's portfolio
Bolt Biotherapeutics has the highest number of patents in nanomedicine followed by, rare diseases. For nanomedicine, nearly 67% of patents were filed and 100% of patents were granted in Q2 2024.
Breast cancer related patents lead Bolt Biotherapeutics portfolio followed by lung cancer, and triple-negative breast cancer (tnbc)
Bolt Biotherapeutics has highest number of patents in breast cancer followed by lung cancer, triple-negative breast cancer (tnbc), adenocarcinoma, and gastric cancer.
For comprehensive analysis of Bolt Biotherapeutics's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.